glycyrrhizin

AssetAlso called Glizigen + Viusid, NSC-167409, NSC-234419

Inhibits HMGB1 activity and has anti-inflammatory and antiviral effects.

Stage
Phase 3, no development reported
Modality
Small molecule
Target
Not known
12
Indications
7
Trials
1
Developer

No development reported since June 2023. Last activity: Trial NCT05916911 registered. clinicaltrials.gov

Indications

12

9 more

In the full profile

  • Owner and partners1
  • Trials7
  • Evidence for its targets1
  • Competitors12
  • Signals14

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets